The Underutilization, Adverse Reactions and Efficacy of Statins after Liver Transplant: A Meta-Analysis and Systematic Review
| Autor: | Cheng Han Ng, Nicholas Chew, Hui Ning Lim, Zhi Hao Ong, Gwyneth Kong, Mark D. Muthiah, Audrey Su-Min Koh, Yeung Jek Ho, M. Shadab Siddiqui |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Statin RD1-811 medicine.drug_class Population 03 medical and health sciences 0302 clinical medicine Internal medicine Hyperlipidemia medicine hyperlipidemia 030212 general & internal medicine Adverse effect education education.field_of_study business.industry Incidence (epidemiology) statin medicine.disease Meta-analysis Hepatocellular carcinoma 030211 gastroenterology & hepatology Surgery graft rejection business Dyslipidemia post-liver transplant |
| Zdroj: | Transplantology, Vol 2, Iss 25, Pp 264-273 (2021) |
| ISSN: | 2673-3943 |
| Popis: | (1) Background: Treatment of dyslipidemia via statin therapy in the non-liver transplant (LT) population is associated with a mortality benefit; however, the impact of statin therapy in post-LT population is not well-defined. This meta-analysis seeks to investigate the safety and efficacy of statin therapy in post-LT patients. (2) Methods: A systematic literature search on Medline and EMBASE database was conducted. A single-arm proportional meta-analysis and conventional pair-wise meta-analysis were performed to compare different outcomes with a random effects model. (3) Results: A total of 11 studies were included in this study, with 697 LT recipients identified to be on statin therapy. Statins were underutilized with only 32% (95% CI: 0.15–0.52) of 1094 post-LT patients on therapy. The incidence of adverse events of 14% (95% CI: 0.05–0.25) related to statin therapy was low. A significant mortality benefit was noted in patients on statin therapy with HR = 0.282 (95% CI: 0.154–0.517, p < 0.001), and improved lipid profiles post LT. The use of statins also significantly decreased odds of graft rejection (OR = 0.33; 95% CI: 0.15–0.73) and hepatocellular carcinoma (HCC) recurrence (HR = 0.32, 95% CI: 0.11–0.89). (4) Conclusions: Statin therapy is safe and efficacious in post-LT patients. Future studies to evaluate the effects of interactions between statins and immunosuppressant therapy are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|